1
EXHIBIT 10.3
AMENDMENT NO. 1
TO OPTION AGREEMENT
This Amendment No. 1 (the "Amendment") to the Option Agreement (the
"Option Agreement") is made effective as of February 5, 1998 (the "Effective
Date") by and between Corixa Corporation, a Delaware corporation having its
principal place of business at 0000 Xxxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxx,
Xxxxxxxxxx 00000 ("Corixa") and SmithKline Xxxxxxx Biologicals Manufacturing
S.A., a Belgian corporation with its principal place of business at Xxx xx
x'Xxxxxxxx 00, X-0000 Xxxxxxxxx, Xxxxxxx ("SB").
RECITALS
WHEREAS, Corixa and SB entered into the Option Agreement dated as of
March 1, 1997 pursuant to which Corixa granted SB an option to enter into
agreements for antigens for vaccine products for the prevention and/or treatment
of colon and/or ovarian cancers in accordance with the terms of the Option
Agreement.
WHEREAS, Corixa and SB now wish to amend the Option Agreement as
hereinafter provided.
NOW, THEREFORE, the parties hereby agree to amend the Option Agreement
as follows:
1. The following shall be inserted in Sentence 1 of Section 2(a) and
Section 3(a) between "in the Collaboration Agreement" and "; provided, that the
parties acknowledge":
", as amended from time to time, including without limitation, by
Amendment No 1. dated February 5, 1998"
2. Except as expressly modified herein, the Option Agreement shall
remain in full force and effect in accordance with its terms.
IN WITNESS WHEREOF, each of the parties hereto has caused this Amendment
to be executed by its duly authorized officer as of the date first written
above.
Agreed to and accepted by: Agreed to and accepted by:
CORIXA CORPORATION SMITHKLINE XXXXXXX
BIOLOGICALS
MANUFACTURING S.A.
/s/ Xxxx XxXxxx /s/Jean Stephenne
By:________________________________ By:____________________________
Xxxx XxXxxx Jean Stephenne
Chief Operating Officer Senior Vice-President
General Manager
